BENITIONSClinical Trial Intelligence

Oral Sodium to Preserve Renal EfficiencY in Acute Heart Failure

不适用 进行中(已停止招募) NCT04334668

适应症Volume Overload
分期不适用
申办方The Cleveland Clinic
状态进行中(已停止招募)
受试者人数67 人
干预(药物)Oral Sodium Chloride
开始日期2020年5月20日
完成日期2022年6月1日
结果公布日2024年3月12日

摘要

The investigators are proposing a prospective, randomized, double blinded, placebo-controlled single center study evaluating the role of co-administration of oral sodium chloride (NaCl) with intravenous diuretics in patients hospitalized with acute decompensated heart failure. The investigators are approaching this study with the hypothesis that the use of oral sodium chloride leads to improved effective diuresis (as measured by weight loss) and renal function as compared to placebo in patients hospitalized with acute decompensated heart failure undergoing aggressive intravenous diuretic therapy.

Change in Weight

Baseline to 96 hours · Kilograms

Oral Sodium Chloride-3.9 ± 4.3 Kilograms
Placebo-4.6 ± 4.2 Kilograms

Change in Creatinine

Baseline to 96 hours · mEq/L

Oral Sodium Chloride0.038 ± 0.39 mEq/L
Placebo0.15 ± 0.44 mEq/L

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。